IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP) Q1 2026 Earnings Call dated Aug. 08, 2025
Corporate Participants:
Unidentified Speaker
Abhay Raj Singh — Vice President & Company Secretary
Pardeep Kumar Khanna — Chief Financial Officer
Analysts:
Unidentified Participant
AB Rafe — Analyst
Priti Agarwal — Analyst
Surabhi — Analyst
Devanshi Shah — Analyst
Maulik Varia — Analyst
Vignesh Iyer — Analyst
Raj Patel — Analyst
Dheeraj Shah — Analyst
Presentation:
operator
Ladies and gentlemen, good day and welcome to IOL Chemicals and Pharmaceuticals Limited Q1FY26 earnings conference call. As a reminder, all participant lines will be in listen only mode and there will be opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing Star then zero on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Prachi Amre from MUFG Investor Relations Team. Thank you and over to you, Ma’. Am.
Unidentified Speaker
Good afternoon everyone and welcome to IOL Chemicals and Pharmaceuticals Limited Q1FY26 earnings conference call today. On the call we have Mr. Pradeep Kumar Khanna, Chief Financial Officer Mr. Abhayraj Singh, Senior Vice President and Company Secretary Mr. Kushan Kumar Rana, Director Works and Mr. Rakesh Mahajan, Advisor. Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward looking statements which are completely based upon our beliefs and expectations as of today. The statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Abhay sir for his opening remarks.
Over to you Sir. Thank you.
Abhay Raj Singh — Vice President & Company Secretary
Thank you Prasiji Good afternoon everyone. Welcome to the Q1FY26 earning call of IOL Chemical and Pharmaceuticals Ltd. Thank you for joining us today and for your continued trust and engagement. I hope you have had a chance to review our financial results and investors presentation available on the Stock Exchange and our website. We are pleased to report an increasing start to the financial year. Q1 FY26 has been a quarter of efficient execution marked by revenue growth, margin expansion and resilient cash flow. This performance reflects the strength of our integrated business model and the strategic clarity with which we are navigating both opportunities and challenges.
Let me begin by briefly setting the broader industry context for the pharmaceutical segment which continue to be the cornerstone of our business. The API market entered FY26 with with steady demand across most therapeutic categories. With certain products continue to face pricing pressure and some product prices have bottomed out, the overall demand environment remain stable. We are also witnessing good demand traction in non ibuprofen APIs like metformin, paracetamol, Clopidogrel, Pantoprazole, Fenofabrid and others. Most of these APIs are operating at optimum utilization level indee robust demand and efficient capacity use in regulated market. The emphasis on quality compliance and supply reliability continue to support opportunities for well integrated manufacturers like IUL.
Our newly commissioned 10,800 MGPA fully backward integrated automated paracetamol plant has also commenced export to European and and other regulated markets, positioning us strongly in this evolving landscape. We have also initiated setting up unit 9 weeks by carving out part of existing unit 9 for manufacturing minoxidil and its intermediates, which is expected to be completed by the third quarter of this financial year. Turning to the chemicals segment, Q1FY26 was marked by steady demand but subdued pricing across key products. Market sentiments remain soft due to cautious downstream procurement. Against this backdrop, our successful reach registration under EU regulations for acidic anhydride marks a significant milestone enabling us to expand our footprint across European markets and reinforcing our position in specialty chemicals.
Looking ahead, our strategic priorities remain clear and consistent. We aim to diversify our API portfolio targeting a 50:50 split between ibuprofen and non ibuprofen. We are scaling up exports with growing tractions in regulated markets across the latam, Europe, China and others. Operational excellence remains a core focus supported by backward integration, process innovation and cost leadership. On the sustainability front, we are proud to have earned the EcoVadis silver medal placing IOL among the top 15% of companies globally for environmental, social and ethical performance. With a strong balance sheet, resilient operations and a clear roadmap, we are well positioned to deliver sustainable growth and long term value for all stakeholders.
With this, I now invite our CFO Mr. Pradeep Khanna to share the financial highlight for Q1FY26.
Pardeep Kumar Khanna — Chief Financial Officer
Thank you Abhay Good afternoon everyone. I am pleased to report that quarter one of financial year 26 has been a strong start through the year with robust financial performance across all key metrics. Revenue from operations stood at rupees 552 cr reflecting a healthy 9.8 percentage year on year growth compared to rupees 502 cr. In quarter one of financial year 25, EBITDA for the quarters rose by 19.5% year on year to rupees 69.5 cr up from rupees 58.2 cr in the same quarter last year. This translates to an EBITDA margin of 12.4 percentage and improvement of 102 basis point year on year basis driven by better product mix, cost optimizations and improved capacity utilization.
Profit after tax came in at rupees 34cr marking a 14.4 percentage increase over rupees 29.7cr in quarter one of financial year 25. That margin also improved reflecting our disciplined financial management and operational resilience. On a cash adjusted basis, our performance was even stronger. Cash PAT for quarter one of financial year 26 stood at rupees 55cr compared to rupees 47cr in the same quarter of the last year registering a growth of over 16%. This underscore our strong cash generation capability and the underlying health of our core operations. Our balance sheet remains solid with no leverage, thereby providing us with ample headroom to fund future growth, invest in innovation and pursue long term strategic initiatives while maintaining financial stability.
With that, I conclude my remarks and now welcome any questions you may have. Thank you.
Questions and Answers:
operator
Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touchstone telephone. If you wish to remove yourself from the question queue, you may press STAR and two participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is on the line of AB Rafe from Wealth Catalyst. Please go ahead.
AB Rafe
Thank you for the opportunity. Good afternoon, sir. I have a couple of questions. So my first question is given that paracetamol has seen relatively weak demand over the past few quarters, which in turn has led to subdued demand for acetic anhydride as well. So what is the current outlook for both the segments? Are there signs of recovery and can we expect a strong rebound in demand for both paracetamol and acetic anhydride?
Unidentified Speaker
Good afternoon. As regarding paracetamol, the prices are no doubt at very low level. But the demand is there, not at that level which was during that period. But it is already above the pre Covid arena area. The demand level is more than pre Covid area. Maybe some growth rate of 3,4% in paracetamol. So no doubt the prices of acetic anhydride are so down presently. But the cost of production for IUL CP maybe to some extent better than other other peers for Astigma anhydride and for paracetamol also. Further, our new plant of 10,810, it is totally atomized and with integration of paraminophenyl and acetic anhydride, we think that we may cover up a certain capacity utilization in FY26.
Maybe around 55 to 60% this year and at a optimum level in next financial year.
AB Rafe
Okay.
Unidentified Speaker
All right.
AB Rafe
So my second question is with a major ethyl acetate plant in the Middle east that has got recently shut down, are we seeing any noticeable Increase in our volumes and prices due to this development. Sir.
Unidentified Speaker
I think we have not shut down any.
Unidentified Participant
They are asking. At least there is a plan shut. I think. I think we have not seen any encouraging change in with respect to the pricing because pricing is totally bottomed out for ethyl acetate. But yes, we have exports for ethyl acetate but they are in line with our previous trends only.
AB Rafe
Okay.
Unidentified Speaker
Okay.
AB Rafe
So some last question is how has been the demand in Europe for both our pharmaceuticals and chemicals portfolio?
Unidentified Speaker
They are good, sir, because like as we talk about our API products. API we have the CEP for most of our products. The demand is slowly and gradually increasing as the approval process is going on from our customer side also.
AB Rafe
Okay, thank you sir. That’s it from my side. Thank you very much.
operator
Thank you. Before we take the next question, we would like to remind participants to press STAR and one to ask a question. The next question is from the line of Preeti Agarwal from SK Associates. Please go ahead.
Priti Agarwal
Yeah, thank you so much for the opportunity. My first question is that how is the demand environment evolving for ibuprofen and paracetamol particularly in the context of post Covid normalization and recent recovery trends.
Unidentified Speaker
I think demand. I think there is no any hafty increase in the demand. But yes, slowly the demand is going.
Unidentified Speaker
Up and which you can see from.
Unidentified Speaker
Our performance also we are increasing our capacity of paracetamol efficiency of our paracetamol plant slowly and gradually increasing the capacity. Ibupromophen? Yes, some, but it is same as compared to our previous quarters only.
Priti Agarwal
Okay, and what are the current price realizations for ibuprofen, paracetamol and metformin in key markets and how are these pricing trends shaping up?
Pardeep Kumar Khanna
The price of ibrofen in the market is 9 to 10$. And in case of metformin it is around 2.523 $. And in case of paracetamol it is 3 to 3.5 USD.
operator
As there’s no no response from the current participant, we would move to the next question. Thank you. The next question is from the line of Shurbi from NV Alpha. Please go ahead.
Surabhi
Hi, thanks for the opportunity. So my first question is how much of our ibuprofen is in regulated market versus the non regulated market. And secondly, all the new APIs that you all have announced for the likes of minoxidil and all, what is the peak revenue that we can do from the newer APIs.
Surabhi
As regarding the export of ibufena regulated market in the out of total export of Ibu Rufus around 70% in our regulatory market primarily Europe and Latin Americans and balance 25 to 30% in non regulated market. And also as regard to your second question in minoxidil we are setting up a capacity of around 120 ton of minoxidil and at the peak level we.
Surabhi
Are.
Surabhi
Expecting a revenue of 50 to 60 from monoxidil in addition to the intermediate sale.
Unidentified Speaker
Got it. Just a follow up. So ibuprofen, we don’t do any North America. Correct. It’s just Europe and Latin.
Unidentified Speaker
Yes, primarily these are the two markets.
Surabhi
And what is the peak revenue that we can do from other APIs from the new block that we have put?
Unidentified Speaker
You’re talking about other API molecules or.
Unidentified Speaker
Other than other than other than. Yeah. IO and other APIs. What is the non ibuprofen, what is the peak revenue that we can do?
Unidentified Speaker
Around.
Surabhi
9, 900 to 1,004 in two to three years.
Unidentified Speaker
Okay.
Pardeep Kumar Khanna
Currently we are approximately at 500.
Unidentified Speaker
So we can double from two three.
Pardeep Kumar Khanna
Year we will achieve eight to 900.
Surabhi
Okay, thank you.
Pardeep Kumar Khanna
We are targeting 50. 5050 Ibu and 50 non Ibo.
Unidentified Speaker
Okay. Yeah. Thank you sir.
operator
Thank you. The next question is from the line of Devanshi Shah from SDA Finance. Please go ahead.
Devanshi Shah
Hi. Thank you for taking my question. So my first question was how much of your chemical production is currently consumed internally for backward integration. Especially for ibuprofen and other versus sold externally through merchant sales.
Unidentified Speaker
It depends on the product to product like isobutyl, benzene, IBV we consume around 75 to 80% in our in house for captive consumption and balance.
Unidentified Speaker
For merchant sales. And then about it highly cited. That is 100% approximately for the merchant sales only. And if you talk about acetic anhydride. Acetic anhydride. We are using almost 40% in house because it is used in MCA and acetyl plant as well as for our paracetamol plant and rest it is for the merchant sales only.
Unidentified Speaker
When the paracetamol capacity will increase, the.
Unidentified Speaker
Inductive consumption will increase.
Devanshi Shah
Got it. So and my second question was how are you transitioning from a domestic unregulated player to a global supplier regulated market. What is the current domestic versus export revenue split and how do you expect this to evolve over the next two, three years?
Pardeep Kumar Khanna
Actually current situation of a holder and domestic domestic is 75% approximately and 25 export and we are targeting to increase the sport to 40% of total revenue in the coming two years.
Devanshi Shah
Got it. And how are you transitioning from a domestic unregulated player to a global supplier in regulated markets?
Pardeep Kumar Khanna
Actually, our new products which are set up in the last two, three years like Clopidogrel, Pentapur and Feno fabric. We are converting it to regulator market. The consumers and the customers are coming for audit. And we hope we will do our best and participate in regulator market in the coming two years. We will achieve our total target of 40% of our food in the coming two years.
Devanshi Shah
Got it, sir. Thank you. And all the best.
operator
Thank you. The next question is from the line of Malik Varia from BNK Securities. Please go ahead.
Maulik Varia
Yeah.
Maulik Varia
Hi sir.
Maulik Varia
Thank you for the opportunity. Just two clarifications. So the 40% expense guidance which we said is for chemicals plus pharma or only pharma APS total for chemical and.
Pardeep Kumar Khanna
Pharma company as a whole.
Maulik Varia
Okay, thank you, sir. And also just one more clarification. Our non IBU share for 1Q would be 34%. Right? Okay.
Unidentified Speaker
Okay.
Maulik Varia
Thank you so much.
Unidentified Speaker
Thank you.
operator
Thank you. The next question is from the line of Vignesh Iyer from Sequent Investments. Please go ahead.
Vignesh Iyer
Hello. Two questions from my side, sir. Firstly wanted to understand all the para set amount prices that you said around 3 to 3.5 dollars. That is the domestic price, right? What. What would the export realization look like?
Unidentified Speaker
It is the average realization to the company as a iol. It may be mix of domestic prices and food prices.
Pardeep Kumar Khanna
Generally export prices are higher than 10 to 20% from the domestic price.
Vignesh Iyer
Okay. Okay. Fair enough. And wanted to understand maintaining our guidance of 15 margins including other income for the entire year.
Pardeep Kumar Khanna
Yes.
Vignesh Iyer
Okay, sir.
Unidentified Speaker
Okay.
Vignesh Iyer
Just one more clarification. I wanted to understand on metformin side. What would be our current utilization of the total capacity? If I’m not wrong, it is around 7,600. So any plans to expand that capacity?
Abhay Raj Singh
Yeah, it’s more than 90% as of now.
Unidentified Speaker
Yes.
Vignesh Iyer
Okay. And any expansion?
Abhay Raj Singh
Expansion. See, see, we already explained this in earlier consensus also by virtue of just setting up the new paracetamol plant earlier plant where we were making the paracetamol that was previously being used for the mat forming. Once we shift all the productions to the new plant of paracetamol, that plant will be used for the metformin again. So that is having the capacity. That will be having the capacity of 4,000. 4,000.
Vignesh Iyer
4,000 MDPA. Right.
Abhay Raj Singh
So will be an additional from now.
Vignesh Iyer
Okay.
Vignesh Iyer
Yeah. 4,000 addition to what we have. Right. So for this the DCDA that is required would which still be continuing to import from China or how. How would. How should we see that part?
Abhay Raj Singh
It will be continue to be imported from China.
Vignesh Iyer
Okay sir. Okay, sir. Got it. That’s all from my side. And all the best for the year ahead.
Unidentified Speaker
It is not domestically.
Abhay Raj Singh
It is not available actually.
Vignesh Iyer
Right.
operator
Thank you. The next question is from the line of Raj Patel from RK Securities. Please go ahead.
Raj Patel
Hello. Am I audible?
operator
Yes, you are.
Raj Patel
Yeah. So thank you for the opportunity. Few quick questions from my side. So I just want to know that can you provide a few more details regarding the my mini oxide mini oxidil expansion project and what will be the strategic role that the unit 9B is going to play within your non ibuprofen portfolio? And apart from that, how do you look its contribution to the growth following its commission which we expect in December 2025?
Unidentified Speaker
Yeah. So basically as you know we have a earlier plant which was used for manufacturing of gabapentin. So it was having two parts. So out of that one part is converted into dedicated facility of minoxidil. And why this minoxidil is selected? The reason is minoxidil was a product which is having good demand from some of our customers. Number one. And number two, the product was already there on shelf. All the validation, all stabilities, all shelf life was assigned to that product. So within no time and addition to the API sales, there are some intermediates of this product which are also going into the market.
So we are selling intermediates of this product into the market as well. So initially once we are not in a position to fully utilize the 100 capacity into API. But yes, intermediates would be there into the market.
Raj Patel
Okay. And my other question was that what can we expect could be a broader strategy for strengthening your non ibuprofen API portfolio, particularly the one which are in high demand therapeutic category. And can you also provide us the more insights or details regarding your product pipeline? Bu ibuprofen.
Unidentified Speaker
So other products, if you see like we have clopidogrel, we have pantobrazole sodium. So all non ibo products, we are converting the markets into the regulated market. We have the presence in Indian market. But yes, we are planning to shift to the quality customers or you can say into the regulated markets where the realization would be better for the product. That is why we are thinking to increase the overall percentage of non ibuprofen products.
Raj Patel
Okay. And my last question was that can you give us some light regarding the non ibuprofen APIs which are being Showing this strong domestic momentum and what are the key growth driver for it? Such as we could expect the regulatory approvals of price stability or increasing geographical penetration.
Unidentified Speaker
So if you see non ibuprofen we are talking about Metformin first where we are utilizing our capacity more than 90%. Then Clopid Doggrel and Pantoprazole are the two other products where also we are increasing towards utilization of capacity more than 70 80%. And the third and most important factor is shifting of all these products to the regulated market. That will be in the only added advantage for conversion of non ibuprofen share into the better percentage.
Raj Patel
Yeah, that was all from my side. Thank you for answering the questions.
operator
Thank you. The next question is from the line of Dheeraj Shah from RJ Investments. Please go ahead.
Dheeraj Shah
Hello. Am I audible?
operator
Yes, you are.
Dheeraj Shah
Yeah. Hello. Thank you for taking my questions. So I have a couple of questions. Firstly, what are the plan developments for the newly acquired 100 acre land parcel near the Chandigarh Bhatinda highway once regulatory approvals are secured?
Unidentified Speaker
So I think already as we informed in the last meeting also the environmental clearance process is already initiated. So public hearing is also complete. And the meeting in the ministry has also been happened on 29th of July. So we are just about to get the environment clearance from the ministry. And parallel we will be planning to start the process slowly because we have the plans to go for chemicals and APIs in that plant also.
Dheeraj Shah
Understood sir. And my second question is that what is the projected CAPEX for financial year 26 and are there any new facilities or strategic initiatives planned under this investment?
Pardeep Kumar Khanna
As we earlier said that our CAPEX for the last two three years 150cr to 200cr annually. So this year we also plan for 150 to 200cr. And this capex is for growth capex and also infrastructure, land and new software and automation in the current year. So we have the same plan as earlier. So the details of the growth CAPEX will be shared on quarterly basis as and when the working and approvals are matured and we will inform accordingly. So plan for 150 to 200cr for the grantee.
Dheeraj Shah
Understood sir. Also despite a challenging macroeconomic environment I has delivered strong top and bottom line growth. So what are the key factor driving this improved traction and performance. Could you highlight that?
Pardeep Kumar Khanna
Actually thank you for your comments. And actually we are focusing on our capacity utilization and efficiency efficiencies and also focusing on backward integration. So these factors contributing best to our performance.
Dheeraj Shah
Understood sir. And lastly what is the current capacity utilization for paracetamol and what are your plans to further scale production and how do you anticipate this impacting revenue contribution and margin for financial year 26 onwards?
Pardeep Kumar Khanna
Currently we are using 34% capacity in the first quarter and we hope it will increase to 60% by quarter three of the current year. And as you know we have fully automatic and backward integrated plant of paracetamol. So we are hoping that we are cost competitive to other other peers. With the other peers. So capacity we hope 60% by the third quarter of the current year.
Dheeraj Shah
Understood sir. That’s all from my side. Thank you for answering my question.
operator
Thank you, thank you. The next question is from the line of Sheikh Mohammed Diaz from an individual investor. Please go ahead.
Unidentified Participant
Thank you for the opportunity and congratulations for the improved set of numbers. My questions, Few of our questions are there. My first one is regarding Ibuprofen. SMS Pharma has started a new plan. I just want to know that is manufacturing facility of SMS Pava more advanced than our and what competition we are facing on that unit. Hello.
operator
Please allow them a moment.
Unidentified Speaker
SMS Pharma, the plant you are talking about that is not new this year. That plant is running since last more than two years number one. Number two, when we talk about the product, the product, the route they are adopting for making ibuprofen that is a different route. So we have the competency with our own process and they have the competencies with their own process and probably for their other processes. We don’t want to comment anything because yeah, that is our peer or competitor you can say.
Unidentified Speaker
Okay sir, previous quarter I have asked regarding the patent of EPIC 7 and in presentation you have mentioned we are having three patterns. So pattern drugs we are having Citagliptin we are having. Which is the third Pixaben Is that the third patent? I just want to know and I am following your LinkedIn page also in that I have seen somewhere that we have filed a patent of Pixaban or Adoxab and exactly. I don’t know last quarter also I have asked the question but I haven’t got the answer yet.
Unidentified Participant
I think. I think one patent is on Cetagliptin that is for sure. Second one is probably on builder Glyptin.
Unidentified Participant
I.
Unidentified Participant
If you give me some time we’ll check and come back to you.
Unidentified Speaker
But how to contact me? Will you contact me or. Because last quarter also that was. The answer was the same that you see right now.
Abhay Raj Singh
Another is the Volsartan and ctaglyptin we have only 2 third is in pipeline. It’s filed not received.
Unidentified Participant
Okay, can you name that drug Apexaben or you do you are not aware of that file One.
Abhay Raj Singh
Just a moment.
Unidentified Speaker
Basically we have three patents sir. So one is on Valsartan, second is on and third is on Losartan.
Unidentified Participant
Losartan. Okay. So that is basically certain drugs right under. Okay sir, my next position is again regarding. Sorry for asking again but what is the. What is the time and regarding US FDA still you have not received any communication regarding US FDN inspection and how much we are exporting in the US market and what are the effects of 50% tariff that Trump sir has announced.
Abhay Raj Singh
So as you said, the Trump sir has announced. We don’t know what is it is going to the next announcement. Number one. Number two, we are not directly impacted with any tariffs so far because API has not been considered so far and there is no tariff has been announced. Number two, as you said U.S. fDA. U.S. fDA approval. We are approved for other products also. So it is not necessary that the US FDA is coming and acting. They are also approving our products for selling into the US Market without even inspection. Like Metformin is. We are allowed to sell the Metformin but every time metformin is there.
Fenofibrate is also approved.
Unidentified Speaker
By the last two months back we have received the approval for Phenofibrid and Labitracetam. We have received the queries from US fda. I think in last week some observations are there on our dmf. So I think. I think the process is still going on.
Abhay Raj Singh
And Mr. Sec. We also need to understand that it is not necessary that the US FDA is come and physically inspect us because they inspected us twice. And after that we have faced so many audits from so many regulatories and all those regulatory audits has been cleared in one go. So they are also considering the other.
Unidentified Speaker
Agencies or approvals like we have and visa like we have eugenp. Our next UGMP is planned in month of November. So all these regulatory bodies they have their own mutual agreement also. So they are considering the audits from other agencies as well.
Unidentified Participant
Great to hear that. That was the satisfactory answer. Sir. What why raw material prices has expended has raised so much from 320 through 323 to 376 crores. Any reason behind that?
Abhay Raj Singh
Sir, can you please come come again. Raw material.
Pardeep Kumar Khanna
Raw material expenses.
Unidentified Speaker
I think there is a rise of 50 crores. We have top line. We have improved 50 crores and raw material prices also increased around 50 crores. So raw material price has increased.
Pardeep Kumar Khanna
Actually, actually you see the change of inventory. We have increased the inventory of finished goods by 12cr. So considering this then you compare it.
Abhay Raj Singh
12Cr is to be deducted.
Unidentified Participant
Yes.
Unidentified Speaker
Okay. Since so long we are discussing regarding the EBITDA margins. 15 to 20% is around. We have what we have, we are, we are discussing most of the time but still it has, it hasn’t been achieved. When do you think we can achieve those 15 to 20% of margins, EBITDA margins?
Pardeep Kumar Khanna
Actually you see last year for the financial year 25 we have had 10 to 11 percentage. Now we are near to 13 percentage. So we hope we will achieve shortly 14 to 15%. And you see the growth from the last two three quarters. Our ETA margin is better.
Abhay Raj Singh
Yeah, we are having very clear cut and focus vision and we are just going. All those R strategies are just getting through. So we are pretty sure that we will be having it. It’s a matter of some time only.
Unidentified Speaker
Okay so in top line we haven’t achieved the 600 crore top line mark. Can we achieve those numbers in next 2 3/4?
Abhay Raj Singh
I think yeah we can. If you, if you see our guidelines I think you’ll find our answers if not 600, but very near to that also.
Unidentified Speaker
Yeah we have achieved 587 is the top I think but haven’t crossed it yet.
Abhay Raj Singh
So what I’m saying in within this financial year we are having three quarters to be reported. So what I’m saying 600 marks is possible. We can touch. If not touch then we will be very close to that.
Unidentified Participant
Okay, that’s great. This is my last question. Price difference between acidic anhydrate in the regulated and India means normal market and regulated market not very much.
Abhay Raj Singh
It’s a very minor 5 to 10% depending country to country.
Unidentified Participant
Okay sir, that was my last question. Thank you.
operator
Thank you. A reminder to the participants, you may press star and one to ask a question. The next question is from the line of Molik Warrior from BNK Securities. Please go ahead.
Maulik Varia
Thank you again for the opportunity sir. So just continuing on the guidance and financial part. So you mentioned that we will be achieving EBITDA margin of 15% plus in the next few quarters. And I think our previous quarter guidance was in FY26. So are we sticking to that guidance of achieving 15% in FY26?
Abhay Raj Singh
We never said that we will be crossing the 15% mark. We are saying that last year we were having something around 12%. This year we are close to 13% by now and what we are estimating and that we will be reaching somewhere 14 to 15% something. But it is not like that that we are saying that the 15% plus so 14, 15% is the guidelines we given. So we are hopeful as of now also.
Maulik Varia
And for chemicals segment, how much EBITDA margin are we expecting? For FY26?
Pardeep Kumar Khanna
It is 5 to 6%. We are hoping.
Maulik Varia
Okay. For FY26 5 to 6%.
Pardeep Kumar Khanna
And from both the sectors.
Maulik Varia
Sorry sir.
Abhay Raj Singh
So this 14% is something blended EBIT margin we were discussing.
Maulik Varia
Yeah, yeah. Right, right. And around 5 to 6% EBIT margin for chemical segment. Right.
Abhay Raj Singh
Yeah.
Maulik Varia
Okay. Okay. And on the revenue front, sir, are we confident of achieving around 10 to 15% revenue growth on a blended basis?
Pardeep Kumar Khanna
Yes, we are expecting 10% growth from the last year. In the current year we definitely achieve.
Abhay Raj Singh
Yeah, we are hopeful.
Maulik Varia
Okay, okay. Okay. Got it, sir. Thank you so much. Thank you.
operator
Thank you. The next question is from the line of Preeti Agarwal from Skushee. Please go ahead.
Unidentified Participant
Yeah, thank you. For the follow up. I wanted to know what is the estimated peak revenue potential for both ibuprofen and non ibuprofen segments over the next few years? And additionally, how do you anticipate margins evolving with the changing product mix and expanding market exposures? So.
Pardeep Kumar Khanna
So from the I and non IU segment we are target targeting 2000cr in the next two years.
Unidentified Participant
Okay, understood. And with the successful reach registration of ascetic anhydride, how do you plan to capitalize on this opportunity for expansion in the EU market? And are there specific volume or revenue targets associated with this initiative?
Pardeep Kumar Khanna
Actually, in case of astrotanade, our captor consumption is increasing due to increase in the capacity of our parasita mole plant which are currently running at 34%. And we are hoping 60% capacity of para by a quarter three of current year. So most of the production of asset energy is captive consumption used in capital consumption only some part surplus part we will sell in the.
Pardeep Kumar Khanna
Market.
Pardeep Kumar Khanna
And we are focusing this surplus quantity to the market where price realization is better. I think in Europe market and for which we have recently got Reach certification.
Unidentified Participant
Okay, understood sir. Thank you so much.
operator
Thank you. Ladies and gentlemen. Due to interest of time, this was the last question. I now hand the conference over to the management for the closing comments. Thank you. And over to you sir.
Unidentified Speaker
Thank you everyone for joining us today. As we concludes our quarter one February 26th earnings call, it is encouraging to see our strategic efforts on education portfolio diversification and regulatory advancement. Translating into strong start to the year. Despite a dynamic external environment, our integrated business model, expanding global footprints and disciplined financial approach continue to reinforce our resilience and growth potential. We remain committed to scaling our presence in both domestic and and the regulated international markets backed by operational excellence and innovation. We appreciate your continued support and look forward to engaging with you as we build on this momentum through the rest of FY26.
For any further queries, please feel free to reach out to our Investor relation team. Thank you once again and have a great day.
operator
Thank you. On behalf of IOL Chemicals and Pharmaceuticals Ltd. We conclude this conference. Thank you for joining us and you may now disconnect your lines.